Approximately 20% of patients with non-small cell lung cancer (NSCLC) are diagnosed with stage III disease. There is currently no consensus on the most appropriate treatment for these patients.

On June 21, 2023, Nature Reviews Drug Discovery published an article titled "Trends in the approval of cancer therapies by the FDA in the twenty-first century."

For patients with early-stage epidermal growth factor receptor mutation-positive (EGFR-M+) non-small cell lung cancer (NSCLC), adjuvant chemotherapy after radical surgery is considered the standard of care.

Patients who have just been diagnosed with non-small cell lung cancer have raised a common question: "What should I do if the first genetic test shows no mutation? Do I need to retest?" Regarding this issue, I would like to propose the following ideas from the perspective of genetic testing for your reference.